Ph 3 PRESERVE 2 trial of Cosela in mTNBC to continue to final analysis following IDMC recommendation February 26, 2024
First Patient Dosed in Ph 1/2 Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors February 26, 2024
Dosing Initiated in Second Cohort of Ovarian Cancer FSHR-targeting CER-T Clinical Trial February 26, 2024
First Subject Dosed in Ph 1b/2 Study of Ampligen® + Imfinzi for the Treatment of Pancreatic Cancer February 26, 2024
REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer initiated February 26, 2024
First Patient Dosed in Ph 1b/2 Trial of Samuraciclib + Vepdegestrant in Patients with Advanced Breast Cancer February 26, 2024
Ph 2 Portion of ALKOVE-1 Trial for Patients with ALK+ve NSCLC and other Solid Tumors initiated February 26, 2024
First Patient Dosed in Ph 1a Study with AVC-201 for the Treatment of R/R AML and other CD123 Heme Malignancies February 26, 2024
2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Ph 2b/3 announced January 31, 2024
First Patient Treated in Ph 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme January 25, 2024
First Patient Enrolled in FIERCE-HN Trial of Ficlatuzumab + ERBITUX® (cetuximab) in Patients with HPV-negative R/M HNSCC January 25, 2024
Enrollment opens for Ph 1b/2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer January 18, 2024
First Dose Cohort in Ph 1 Trial of BP1002 to Treat R/R Lymphoma and R/R CLL Patients completed January 18, 2024
First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer January 18, 2024
Patients enrolled into the 3rd Dosing Cohort of Ph 1/2 Study of ONCT-534 in R/R Metastatic CRPC January 10, 2024
